DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol 300 μg
Drug: Salmeterol 50 μg
Drug: Placebo to indacaterol
Drug: Placebo to salmeterol

First Posted Date: 2007-09-14

Last Posted Date: 2011-08-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 805

Registration Number: NCT00529529

Locations: 🇹🇷
Novartis Investigator Site, Izmir, Turkey
🇺🇸
Novartis Investigator Site x 2 sites, Pensacola, Florida, United States
🇺🇸
Novartis Investigator site, Houston, Texas, United States

and more 1 locations

Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms

Phase 4

Completed

Conditions: Renal Transplant

First Posted Date: 2007-09-14

Last Posted Date: 2017-07-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT00529269

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Phase 1

Completed

Conditions: Hematologic Neoplasms
Breast Cancer

Interventions: Drug: AUY922 2 mg/m2

First Posted Date: 2007-09-06

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 117

Registration Number: NCT00526045

Locations: 🇺🇸
Nevada Cancer Institute Clinical Trials Office, Las Vegas, Nevada, United States
🇺🇸
UCLA/ University of California Los Angeles UCLA, Los Angeles, California, United States
🇺🇸
Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101, Boston, Massachusetts, United States

and more 5 locations

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Phase 4

Completed

Conditions: Hypertension
Diastolic Dysfunction

Interventions: Drug: valsartan
Drug: amlodipine

First Posted Date: 2007-08-31

Last Posted Date: 2012-04-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 229

Registration Number: NCT00523549

Locations: 🇺🇸
Novartis Investigative Sites, USA, New Jersey, United States

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

Phase 2

Completed

Conditions: Advanced Gastric Cancer

Interventions: Drug: Everolimus

First Posted Date: 2007-08-22

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT00519324

Locations: 🇯🇵
Novartis Investigative Site, Tochigi, Japan
🇯🇵
Novartis investigative Site, Tokyo, Japan

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Phase 3

Terminated

Conditions: Myelogenous Leukemia

Interventions: Drug: Nilotinib (AMN107)
Drug: Imatinib

First Posted Date: 2007-08-21

Last Posted Date: 2011-11-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT00519090

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Southern California Permanente Medical Group, San Diego, California, United States

and more 27 locations

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2

Terminated

Conditions: Glioblastoma Multiforme

Interventions: Drug: Everolimus
Procedure: Surgery

First Posted Date: 2007-08-13

Last Posted Date: 2011-09-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT00515086

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Duke University - Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 5 locations

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Everolimus
Drug: Myfortic
Drug: Sandimmun Optoral
Drug: Simulect®

First Posted Date: 2007-08-10

Last Posted Date: 2017-01-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 802

Registration Number: NCT00514514

Locations: 🇨🇭
Novartis Investigative Site, Bern, Switzerland

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

Phase 4

Completed

Conditions: Progressive Gastrointestinal Stromal Tumor

Interventions: Drug: Imatinib mesylate

First Posted Date: 2007-08-02

Last Posted Date: 2020-09-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT00510354

Locations: 🇩🇪
Novartis Investigative Site, Tübingen, Germany

Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting

Phase 4

Completed

Conditions: Atopic Dermatitis

First Posted Date: 2007-08-01

Last Posted Date: 2018-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT00509990

Locations: 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
🇻🇪
Novartis Investigative Site, Edo, Carabobo, Venezuela

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy